Literature DB >> 6342622

Metabolism of spirohydantoin mustard in the mouse. Isolation of an alkylating, mutagenic metabolite.

W J Suling, R F Struck, C W Woolley, W M Shannon.   

Abstract

The metabolism of spirohydantoin mustard (SHM), a central nervous system-directed nitrogen mustard with reported anticancer activity, was studied using both the Salmonella/mammalian microsome mutagenicity assay and radiolabeled drug. SHM had little or no mutagenic activity by itself but was metabolized to a mutagen(s) in the presence of mouse postmitochondrial liver fraction (9000 g supernatant, S9). Metabolism was NADPH-dependent and was enhanced with phenobarbital-induced S9. Both SHM and mutagen(s) were extractable in chloroform. Studies using [14C]SHM, uniformly labeled on the bis(2-chloroethyl)amino group, and thin-layer chromatography (TLC) of chloroform extracts of liver S9 incubation mixtures indicated the formation of a single major metabolite fraction that contained a direct-acting mutagen. Chloroform extracts of both blood and brain from BDF1 mice injected i.p. with SHM (60 mg/kg) were found to be mutagenic in the absence of S9. Also, TLC of chloroform extracts of brain taken 15 min after i.p. injection of [14C]SHM suggested the presence of SHM and the mutagenic metabolite. These results suggest that the mutagenic metabolite may have a significant role in the mechanism of action of SHM.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342622     DOI: 10.1016/0006-2952(83)90533-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  1 in total

Review 1.  Spiromustine: a new agent entering clinical trials.

Authors:  D D Shoemaker; P J O'Dwyer; S Marsoni; J Plowman; J P Davignon; R D Davis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.